What is RCUS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.11B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RCUS?

P/E (TTM) is n/a and 52-week range is $14.26 to $31.73 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RCUS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RCUS?

The company profile lists revenue (TTM) near $117M, net income (TTM) near $-45.88B, EPS (TTM) near $-3.90 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Arcus Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Hayward, California, US, 125.8M shares outstanding, ISIN US03969F1093 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Arcus Biosciences Inc

$RCUS

Health Care · Biotechnology

IR Run Scenarios

$24.41

+2.43%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. The company is headquartered in Hayward, California and currently employs 601 full-time employees. The company went IPO on 2018-03-15. The firm has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The firm has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The firm is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). The company is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Employees

601

Website

arcusbio.com/

IPO

2018-03-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)